Triftazin release form and dosage. Triftazin injections: instructions for use. Contraindications for use

Weakens the effects of levodopa and phenamine derivatives, the latter reduce the antipsychotic activity of trifluoperazine. Enhances the effect of ethanol and other drugs that depress the central nervous system (general anesthetics, narcotic analgesics, opioids, barbiturates), as well as atropine.

When taken simultaneously with antiepileptic drugs (including barbiturates), it reduces their effect (lowers the epileptic threshold).

Reduces the effect of anorexigenic drugs (with the exception of fenfluramine).

Reduces the effectiveness of the emetic action of apomorphine, enhances its inhibitory effect on the central nervous system.

Increases plasma concentration of prolactin and interferes with the action of bromocriptine. When combined with tricyclic antidepressants, maprotiline, monoamine oxidase inhibitors, prolongation and enhancement of sedative and anticholinergic effects is possible, with thiazide diuretics - the occurrence of electrolyte imbalance, with lithium preparations - a decrease in absorption in the gastrointestinal tract, an increase in the rate of excretion of lithium by the kidneys extrapyramidal disorders, early signs of lithium intoxication (nausea and vomiting) can be masked by the antiemetic effect of trifluoperazine.

When combined with beta-blockers, it enhances the hypotensive effect, increases the risk of developing irreversible retinopathy, arrhythmias and tardive dyskinesia. Reduces the effect of indirect anticoagulants.

Antithyroid drugs increase the risk of agranulocytosis. Probucol, cisapride, disopyramide, pimozide, contribute to an additional lengthening of the Q-T interval, which increases the risk of developing ventricular tachycardia.

With the simultaneous use of phenothiazides with propranolol, an increase in the concentration of both drugs is noted.

For the correction of extrapyramidal disorders, antiparkinsonian drugs are used - and others; dyskinesias are stopped subcutaneously by injecting 2 ml of 20% caffeine solution and 1 ml of 0.1% atropine solution).

The drug, having a cardiotoxic effect, can cause arterial hypotension, deterioration of cardiac hemodynamics (pulmonary edema, ventricular fibrillation and, as a consequence of the latter, sudden death) in elderly patients with psychosis.

Elderly patients may develop irreversible dyskinesias. If signs of tardive dyskinesia, neuroleptic malignant syndrome appear, treatment should be canceled.

During therapy with phenothiazines, it is possible to obtain false-positive tests for phenylketonuria.

The appointment of phenothiazines should be discontinued at least 48 hours before the proposed myelography (renewal is possible after 24 hours).

Film-coated tablets, 5 mg or 10 mg.

10 coated tablets in a blister strip made of polyvinyl chloride film and lacquered aluminum foil.

50 or 100 coated tablets in a glass jar, sealed with a plastic lid or in a polymer jar.

The drug "Triftazin", the instructions for which will be detailed in this article, is considered one of the most effective antipsychotics. The use of this drug is associated with many subtleties in terms of dosage and duration of therapy.

Description of the drug, composition

According to the group affiliation, the drug "Triftazin" belongs to strong antipsychotic drugs with a pronounced antiemetic effect. The main active ingredient is a compound from the group of phenothiazines - trifluoperazine, which can affect not only the central nervous system, but also its peripheral parts, due to which, in fact, it has an antiemetic effect.

Solution for injection is a clear, colorless liquid without a specific odor and taste. Tablets "Triftazin" are rounded, blue-coated, white or almost white at the break.

Release form, terms and conditions of storage

The drug "Triftazin", reviews of doctors about which are almost always positive, is available in two dosage forms: in the form of a solution for injection and in tablets. The content of the active substance in each ampoule with a solution is 0.2% (2 mg per 1 ml of solution). Ampoules are packed in cardboard boxes of 5, 10 or 100 pieces together with a special ampoule knife and instructions for use of the drug.

In tablets "Triftazin" the active ingredient is contained in an amount of 0.005% (0.5 mg). They are packed in blisters of 10 pieces, which, in turn, are placed in cardboard boxes of 4, 5 or 10 pieces each. This dosage form is also available in packs of dark glass or opaque white plastic containing 50 or 100 tablets.

The shelf life of all dosage forms is 3 years. The instructions for use recommend to store tablets and Triftazin solution in a cool room with good ventilation. It is unacceptable to get direct sunlight and liquids on the packages with medicines. After the expiration date, it is not recommended to take the drug.

Pharmacological properties of the drug "Triftazin"

Let's consider the main properties of the drug "Triftazin". The instructions for use (official) contain detailed information on the mechanism of action of the active substance of the drug on the receptors of the brain and in the gastrointestinal tract. So, it says that trifluoperazine blocks PMD receptors in the brain and D2 receptors in the cerebellum. In addition, it is able to have an alpha-adrenergic blocking effect, that is, it actively affects the level of blood pressure, reducing it.

Trifluoperazine has not been sufficiently studied in terms of pharmacokinetics, but it is known for certain that it actively binds to plasma proteins (at least 80%). The mechanism of decomposition of the compound into metabolites is also poorly understood. The excretion of the drug from the body occurs mainly through the kidneys, a small part of the active substance and its metabolites is excreted through the intestines (with bile).

Indications for use

Since the action of the drug "Triftazin" classifies the instructions for use as antipsychotic, the range of diseases in which it is advisable to use it includes a variety of mental disorders. These include schizophrenia, psychomotor disorders, anxiety and phobias (uncontrollable obsessive fears). In addition, the drug is used to treat vomiting that is not caused by diseases of the digestive system.

How safe is the drug we are considering and can all categories of patients be used "Triftazin"? Instructions for use, expert reviews about him allow us to conclude that it is necessary to take the drug only after a comprehensive examination, since it has a number of serious contraindications and side effects. Despite the fact that the medicine is dispensed without a prescription, it is not worth making a decision on its reception on your own.

Contraindications

The tablets and solution for injection "Triftazin" have contraindications for use, which imply the impossibility of their use. Among them are the depression of the central nervous system and coma. In addition, the instruction for use does not recommend taking the medicine "Triftazin" for diseases of the heart, liver and kidneys, and of the hematopoietic system. The stage of the disease and the severity of its course do not play a significant role. The fact is that there are a number of consequences of taking tablets and Triftazin solution. The side effects, which will be discussed below, are very serious in themselves, and in the presence of concomitant pathologies, they can provoke even more complex consequences for the patient's body.

Use of "Triftazin" during pregnancy

The active substance of the drug "Triftazin" (doctors' reviews contain a lot of supporting information on this) has a negative effect on the developing fetus. That is why it is categorically not recommended to take the drug during pregnancy. The fact is that the active substance trifluoperazine in the tissues of the fetus is found in concentrations that significantly exceed the therapeutic dose. It is this that provokes a weak set of fetal mass, and also increases the risk of developing various defects in its development.

The drug "Triftazin" (analogs for the active substance should also be taken into account) is not recommended for lactating women, since the components of the drug are found in breast milk. Even if the mother does not observe any side effects, the baby in the future may face such problems as tardive dyskinesia and lethargy.

Side effects

As mentioned earlier, the drug "Triftazin" can cause a number of undesirable reactions from almost all organs and systems. First of all, the active substance affects the patient's nervous system, which means that the lion's share of side effects occurs in it. First of all, they include such phenomena as tremors, cramps of the muscles of the neck and tongue, which can make speech slurred (extrapyramidal reactions). Also, symptoms of tardive dyskinesia, insomnia, akathisia and autonomic disorders often appear.

The most common adverse reactions from the central nervous system caused by taking the drug "Triftazin" are called drowsiness, dizziness and loss of vision clarity. Usually, such symptoms appear on the first day after the start of drug treatment.

What else can cause the intake of solution for injection or tablets "Triftazin"? Side effects, according to the testimony of patients and doctors, often affect the digestive system. It manifests itself in the form of anorexia. Problems with the normal functioning of the liver are also common. In addition, the appearance of allergic amenorrhea, agranulocytosis is possible.

special instructions

The aforementioned undesirable effects can be mitigated by symptomatic therapy or dose adjustments. Cancellation of "Triftazin" is required only in the presence of serious violations in the work of the patient's organ systems. So, we will consider the main techniques and methods of getting rid or mitigating the unwanted reactions of the body to the drug.

When tremors or seizures appear, in most cases, experts decide to reduce the doses of the drug taken by the patient or to temporarily stop taking it. In severe cases, treatment with antiparkinsonian medications, barbiturates or caffeine medications may be required

When pronounced symptoms of insomnia or motor disinhibition, agitation appear, it is not recommended to increase the starting dose of the drug. As a rule, within a few days, the body adapts to the new drug, and the unwanted symptoms gradually disappear. Otherwise, treatment with drugs "Benzodiazepine" or "Propanolol" may be required.

A condition such as tardive dyskinesia, mentioned among the side effects when taking the drug "Triftazin", reviews of which will be presented below, most often develops as a result of prolonged use of the drug or shortly after its cancellation. Experts note that it is most often diagnosed in elderly patients.

Some side effects caused by taking the drug are incompatible with actions such as driving and complex machinery. It is better to refrain from them during the treatment with Triftazin.

The dosage of the drug is determined by a specialist based on the individual characteristics of the patient: his condition and the presence of concomitant diseases. At the beginning of the course of therapy, the minimum doses of the drug "Triftazin" are usually prescribed. Tablets the instruction prescribes to take 1-5 mg 2 times a day (for adult patients). Over the next three weeks, the dosage is gradually increased and brought to 45-60 mg per day. This amount must also be divided into three steps.

For the treatment of children, it is customary to use smaller doses of the drug. At the beginning of therapy, take no more than 3 mg per day (in 3 doses). If necessary and in the absence of pronounced symptoms of adverse reactions, the dosage is increased to 5-6 mg per day.

Solution for injection "Triftazin" must be injected intramuscularly with an interval of no more than 6 hours. The daily dose of the drug for adults is a maximum of 10 mg. Children are shown a dosage of 1 mg per day, divided into 2 injections, with an interval of at least 12 hours.

We draw the reader's attention to the fact that treatment with this drug, regardless of the dosage form used, should be carried out under the supervision of the attending physician. It is he who makes the decision to change the dosage of the drug "Triftazin". Overdose with proper use of the product is almost impossible. Unauthorized prescribing of the drug or changing the recommended doses upwards can lead to unpredictable consequences.

Drug interactions

All drugs tend to interact with each other. Tablets and solution for injection "Triftazin" in this regard are no exception. Usually, experts take into account many factors that affect the effectiveness of prescribing a given drug. So, medicines containing ethanol (syrups, tinctures, etc.) can enhance the CNS depressing properties of "Triftazin", as well as negatively affect the respiratory processes.

Together with drugs that lower blood pressure, tablets or Triftazin solution should be used very carefully, since acute orthostatic hypotension may develop.

Antacids and antiparkinsonian drugs promote less absorption of the active substance of the Triftazin tablets from the digestive tract, and, therefore, reduce the effectiveness of the drug.

A negative effect is also seen when the drug is used together with lithium salts. According to the data obtained, this combination is fraught with the development of pronounced extrapyramidal symptoms and an increase in the neurotoxic effect of trifluoperazine.

Instructions for use:

Triftazinum (Triphtazinum) is an antipsychotic used for the effective treatment of mental disorders and schizophrenia.

Pharmacological action of Triftazin

The medication is an antipsychotic agent with sedative, antiemetic, anti-emetic, hypomeric, cataleptic, hypotensive and mild m-anticholinergic action. Triftazine is structurally similar to chlorpromazine, but it has a higher activity and is better tolerated.

Release form

Triftazin is produced in the form of coated tablets, in cellular packages, in cardboard packs of 10 and 50 pieces or in ampoules of 1 ml of a 0.2% solution of 10 pieces.

Triftazin's analogs

Triftazin-Darnitsa is an analogue of Triftazin in terms of active ingredient. By the mechanism of action and belonging to the same pharmacological group, the analogs of Triftazin include:

• Mazheptil;
• Meterazine;
• Moditen;
• Eteperazine.

Indications for the use of Triftazin

The drug Triftazin is used in cases of schizophrenia, psychosis, hallucinatory and affective-delusional states, psychomotor agitation and vomiting (central genesis).

Method of using Triftazin

In accordance with the instructions, Triftazin tablets are used orally, washed down with plenty of water, or injected intramuscularly in the form of a solution. The dosage of the drug depends on the age and the disease. For the treatment of anxiety syndrome with Triftazin tablets, the dose is 1-2 mg twice a day, the maximum dose is 6 mg per day, for no more than 12 weeks. In the treatment of psychotic disorders, the drug is prescribed in an amount of 2.5-5 mg twice a day, by mouth, with an increase to 15-20 mg per day for 2-3 weeks, the maximum dose is 40 mg per day. The use of Triftazin orally in old age and debilitated patients begins with a lower initial dose, which can be increased if necessary. For children over the age of 6 years, the dosage of the drug is 1 mg 1-2 times a day with a possible gradual increase.

A single dosage of the drug Triftazin with intramuscular administration is 1-2 mg every 4-6 hours, but not more than 10 mg per day. In accordance with the instructions, Triftazin is prescribed for elderly people, as well as for weakened and emaciated patients, in the initial dose, reduced by 2 times. For children over the age of 6 years, the dosage of the medication is 1 mg 1-2 times a day.

Contraindications

According to the instructions, Triftazin is contraindicated for use when:

• Violation of renal excretory function;
• Severe liver failure;
• Oppression of bone marrow hematopoiesis;
• Progressive diseases of the brain and spinal cord;
• Traumatic brain injury;
• Coma of any etiology;
• Severe depression of the function of the central nervous system;
• Severe cardiovascular disease;
• Hypersensitivity.

The drug Triftazin, according to the instructions, is prescribed with caution for alcoholism, angina pectoris, valvular heart disease, pathological changes in the blood, breast cancer, angle-closure glaucoma, prostatic hyperplasia, hepatic and renal failure, gastric ulcer and duodenal ulcer.

Also Triftazin, according to the instructions, is used with caution in Parkinson's disease, epilepsy, myxedema, Reye's syndrome, cachexia and vomiting.

The drug Triftazin is prescribed with caution in old age, it is not prescribed for children under the age of 3 years, for pregnant women and during lactation.

Side effects of Triftazin

According to reviews, the use of Triftazin can lead to complications from various body systems in cases of overdose, namely:

• Nervous system: insomnia, dizziness, drowsiness, akathisia, parkinsonism, tardive dyskinesia, dystonic extrapyramidal reactions, neuroleptic malignant syndrome, phenomena of mental indifference, mental changes and a delayed reaction to external stimuli;
• Endocrine System: hypoglycemia, glucosuria, hyperprolactinemia, galactorrhea, pain or swelling in the mammary glands, amenorrhea, hyperglycemia, dysmenorrhea, and weight gain;
• Genitourinary system: oliguria, decreased potency, priapism, frigidity, decreased libido, impaired ejaculation and urinary retention;
• Digestive system: nausea, decreased appetite, dryness of the oral mucosa, constipation, gastralgia, bulimia, anorexia, vomiting, diarrhea, cholestatic jaundice, hepatitis and intestinal paresis;
• Hematopoietic organs: leukopenia, thrombocytopenia, pancytopenia, agranulocytosis, eosinophilia and hemolytic anemia;
• Sense organs: visual impairment (paresis of accommodation), clouding of the lens and cornea, retinopathy and blurred vision;
• Cardiovascular system: decrease or inversion of the T wave, lengthening of the Q-T interval, heart rhythm disturbances and increased frequency of angina attacks.

In addition, according to reviews, Triftazin can cause other disorders, namely:

• Skin rash;
• Angioedema;
• Hives;
• Exfoliative dermatitis;
• Conjunctiva;
• Skin coloring;
• Photosensitization;
• Discoloration of the sclera and cornea;
• Myasthenia gravis;
• Phenylketonuria.

Also, the use of Triftazin according to reviews can lead to the development of heatstroke, loss of the ability to sweat, confusion and false positive pregnancy tests.

An overdose of medication can lead to neuroleptic malignant syndrome, low blood pressure, hypothermia, tachycardia, gynecomastia, coma, collapse and toxic hepatitis.

Storage conditions

In accordance with the instructions, Triftazin must be stored out of the reach of children and protected from light in a dry place, at room temperature up to 25 ° C. The shelf life, subject to the recommendations, is 4 years.

Tradename: TRIFTHAZINE

International non-proprietary name:

Dosage form:

Composition:

Description: Coated tablets of blue color with marbling, biconvex shape with a smooth surface. The cross section shows two layers.

Pharmacotherapeutic group:

ATX code N05AB06

pharmachologic effect
Triftazine is a neuroleptic, from the group of piperazine derivatives of phenothiazine. It has a pronounced antipsychotic and antiemetic effect, has a-adrenolytic and weak anticholinergic and sedative effects. The neuroleptic effect is combined with a moderate stimulating effect (in small doses). Triftazin has a pronounced and lasting effect on productive psychotic symptoms (hallucinations, delusions). Causes extrapyramidal disturbances.

Pharmacokinetics:
It is well absorbed from the gastrointestinal tract and from the sites of parenteral administration. The time to reach the maximum concentration with intramuscular injection is 1-2 hours. The connection with plasma proteins is 95% (therefore, it is poorly dialyzed). It is metabolized in the liver, the half-life is 15-30 hours, most of the metabolites are pharmacologically inactive. It is excreted by the kidneys and with bile. Triftazine crosses the placenta.

Indications for use:

• schizophrenia and other mental illnesses, proceeding with delirium, hallucinations and psychomotor agitation;
• vomiting of central origin.

Contraindications:

• increased individual sensitivity;
• inhibition of the function of the central nervous system (CNS) and coma of any etiology;
• brain injury;
• diseases of the liver, kidneys and hematopoietic organs with dysfunction;
• progressive systemic diseases of the brain and spinal cord;
• peptic ulcer and 12 duodenal ulcer during an exacerbation;
• heart failure in the stage of decompensation; severe arterial hypotension; diseases accompanied by the risk of thromboembolic complications;
• angle-closure glaucoma (risk of increased intraocular pressure);
• hyperplasia of the prostate;
• myxedema;
• pregnancy, breastfeeding period;
• children's age up to 3 years.

Carefully:
Elderly age, vomiting (the antiemetic effect of phenothiazines can mask vomiting associated with an overdose of other drugs).

Triftazine is used after comparing the risks and benefits of treatment in patients with alcohol intoxication, Reye's syndrome, cachexia, as well as breast cancer, Parkinson's disease, gastric ulcer and duodenal ulcer, urinary retention, chronic respiratory diseases (especially in children), epileptic seizures.

Method of administration and dosage:

Doses are selected individually in accordance with the severity of the condition; it is advisable to use dosage forms with an appropriate (lower) dosage for dose titration. When the maximum therapeutic effect is reached, the dose is gradually reduced to a maintenance one. Usually, for the treatment of anxiety conditions, adults are prescribed 1 mg 2 times a day. For patients with psychotic disorders, start 2-5 mg 2 times a day. To obtain the optimal therapeutic effect, the dose is gradually increased to 15-20 mg / day, divided into 2-3 doses, the maximum daily dose is 40 mg.

To obtain the desired therapeutic effect and improve the patient's condition, usually 2-3 weeks are needed.

Children 6-12 years old, with psychotic disorders, are prescribed 1 mg 1-2 times a day, if necessary, this dose can be increased to 4 mg / day. The dose for children over 12 years old is 5-6 mg per day, divided into several doses.

Adults with vomiting - 1-2 mg 2 times a day. For elderly patients, the initial dose of the drug should be reduced by 2 times.

Side effect:

With prolonged use, it is possible to develop tardive dyskinesia, less often - malignant neuroleptic syndrome.

From the senses: paresis of accommodation, with prolonged use - retinopathy, opacity of the lens and cornea.

From the genitourinary system: urinary retention, decreased potency, frigidity, decreased libido, ejaculation disorders, priapism, oliguria.

From the endocrine system: hypo- or hyperglycemia, glucosuria, amenorrhea, hyperprolactinemia, dysmenorrhea, galactorrhea, swelling or pain in the mammary glands, gynecomastia, weight gain.

From the digestive system: dry mouth, decreased appetite, constipation, bulimia, nausea, vomiting, diarrhea, gastralgia, cholestatic jaundice.

From the senses: visual impairment - paresis of accommodation (at the beginning of treatment), retinopathy, opacity of the lens and cornea.

Laboratory indicators: thrombocytopenia, lymph and leukopenia, increased blood clotting, anemia, agranulocytosis (more often at 4-10 weeks of treatment), pancytopenia, eosinophilia - less often than other phenothiazines, false positive pregnancy tests.

From the side of the cardiovascular system: tachycardia, decreased blood pressure (including orthostatic hypotension), especially in elderly patients and those suffering from alcoholism, cardiac arrhythmias, prolongation of the QT interval, decrease or inversion of the T wave. Allergic reactions: skin rash , urticaria, angioedema (less often than other phenothiazines).

Others: pigmentation of the skin and conjunctiva, discoloration of the sclera and cornea, reduced tolerance to high temperatures (up to the development of heatstroke), melanosis.

Local reactions: with intramuscular injection, infiltrates may occur, if liquid forms come into contact with the skin, contact dermatitis.

Overdose (intoxication) with the drug
Symptoms: areflexia or hyperreflexia, blurred vision, cardiotoxic effects (arrhythmia, heart failure, decreased blood pressure, shock, tachycardia, changes in the QRS complex, ventricular fibrillation, cardiac arrest), neurotoxic effects, including agitation, confusion, convulsions, disorientation drowsiness, stupor, or coma; mydriasis, dry mouth, hyperpyrexia or hypothermia, muscle stiffness, vomiting, pulmonary edema, or respiratory depression.

Treatment is symptomatic: for arrhythmias - intravenous (iv) phenytoin 9-11 mg / kg, with heart failure - cardiac glycosides, with a pronounced decrease in blood pressure - intravenous fluid or vasopressor drugs such as norepinephrine, phenylephrine (avoid prescribing alpha- and beta-adrenergic agonists, such as epinephrine, since a paradoxical decrease in blood pressure is possible due to the blockade of alpha-adrenergic receptors with trifluoperazine), for convulsions - diazepam (avoid prescribing barbiturates, due to possible subsequent depression of the central nervous system and respiration), with parkinsonism - diphenyltropine , diphenhydramine. Control of the function of the cardiovascular system for at least 5 days, the function of the central nervous system, respiration, measurement of body temperature, consultation of a psychiatrist. Dialysis is ineffective.

Interaction with other medicinal products
With the simultaneous use of Triftazin with other drugs that have a depressing effect on the central nervous system (agents for general anesthesia, narcotic analgesics, ethanol (alcohol) and drugs containing it, barbiturates, tranquilizers, etc.), it is possible to increase the depression of the central nervous system, as well as respiratory depression;

long-term combination with analgesics and antipyretics is undesirable - hyperthermia may develop;

with tricyclic antidepressants, maprotiline or monoamine oxidase (MAO) inhibitors - an increase in the risk of developing neuroleptic malignant syndrome; with anticonvulsants - a decrease in the seizure threshold is possible; with drugs for the treatment of hyperthyroidism - the risk of developing agranulocytosis increases; with other drugs causing extrapyramidal reactions - an increase in the frequency and severity of extrapyramidal disorders is possible;

with antihypertensive drugs - severe orthostatic hypotension is possible; with ephedrine - it is possible to weaken the vasoconstrictor effect of ephedrine. When treating with Triftazine, the administration of epinephrine (adrenaline) should be avoided, since the effect of epinephrine may be perverted, which can lead to a drop in blood pressure. The antiparkinsonian effect of levodopa is reduced by blocking dopamine receptors. Triftazine can inhibit the action of amphetamines, clonidine, guanethidine. Triftazine enhances the anticholinergic effects of other drugs, while the antipsychotic effect of the neuroleptic may decrease.

With the simultaneous use of Triftazine with prochlorperazine, prolonged loss of consciousness may occur.

The combination with lithium preparations increases the risk of extrapyramidal complications. Triftazine can mask some manifestations of ototoxicity (tinnitus, dizziness), drugs that have an ototoxic effect (eg antibiotics). Other hepatotoxic drugs increase the risk of developing hepatotoxicity. Antacids containing Al 3+ and Mg 2+ reduce the absorption of triftazine.

special instructions
During treatment, it is necessary to carry out regular monitoring of blood pressure, pulse and liver, kidney and blood function.

During the period of treatment, do not allow the use of alcohol!

During the period of treatment, it is necessary to refrain from engaging in potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions.

Release form
10 tablets in a blister strip or 50 or 100 tablets in orange glass or polymer cans. Each can or 5 blisters together with instructions for use in a cardboard box

Storage conditions
List B. In a dry, dark place, out of reach of children.

Shelf life
3 years. Do not use later than the date indicated on the package.

Conditions of dispensing from pharmacies
Dispensed by prescription.

Manufacturer: JSC "Dalkhimpharm", 680001, Khabarovsk, st. Tashkent, 22.